TYRAMEDIUM SIGNALFINANCIAL10-K

TYRA Biosciences accelerated R&D spending by roughly 29% as its lead asset dabogratinib (formerly TYRA-300) advanced through multiple clinical programs, driving a meaningfully wider operating loss and continued balance sheet drawdown.

For a clinical-stage company with no revenue, the roughly 29% increase in R&D expense to ~$102.9M reflects deliberate pipeline investment across urothelial cancer and skeletal dysplasia indications, but it is consuming cash at a faster pace than the prior year. With total assets declining from $363.6M to $282.6M and stockholders' equity compressing from $343.2M to $259.2M, the runway clock is ticking louder, and investors should monitor the pace of data readouts against the remaining cash position of $77.4M. The rebranding of TYRA-300 to "oral dabogratinib" and the expanded clinical narrative — noting over 100 participants dosed across multiple studies — signal a maturing pipeline story, though no near-term catalyst has been disclosed that would bridge the company to profitability.

Comparing 2026-03-02 vs 2025-03-27View on EDGAR →
FINANCIAL ANALYSIS

Operating cash outflow widened from -$69.8M to -$95.1M, consistent with the step-up in R&D spend from $80.1M to $102.9M, and the net loss deepened from -$86.5M to -$119.9M — all reflecting the company's deliberate acceleration of clinical activity. On the balance sheet, cash and equivalents declined modestly from $92.0M to $77.4M, while current assets fell from $347.5M to $265.4M, suggesting the company holds meaningful non-cash liquid assets (likely short-term investments) that are also being drawn down. Capital expenditures fell sharply from $664K to $141K, indicating the company is not investing in fixed infrastructure, but the overall picture signals that TYRA will likely need to access capital markets within the next 12–18 months absent a material non-dilutive milestone.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
-78.8%
$664K$141K

Capex reduced 78.8% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Net Income
P&L
-38.7%
-$86.5M-$119.9M

Net income declined 38.7% — review whether driven by operations, interest costs, or non-recurring items.

Operating Cash Flow
Cash Flow
-36.4%
-$69.8M-$95.1M

Operating cash flow fell 36.4% — earnings quality concerns; investigate working capital changes and non-cash items.

R&D Expense
P&L
+28.5%
$80.1M$102.9M

R&D investment increased 28.5% — signals commitment to future product development, though near-term margin impact.

Operating Income
P&L
-27.4%
-$104.2M-$132.8M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

Stockholders Equity
Balance Sheet
-24.5%
$343.2M$259.2M

Equity decreased 24.5% — buybacks or losses reducing book value, monitor solvency ratios.

Current Liabilities
Balance Sheet
+24%
$14.6M$18.1M

Current liabilities rose 24% — increased short-term obligations, watch current ratio.

Current Assets
Balance Sheet
-23.6%
$347.5M$265.4M

Current assets declined 23.6% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-22.3%
$363.6M$282.6M

Total assets contracted 22.3% — asset sales, write-downs, or balance sheet optimization underway.

Cash & Equivalents
Balance Sheet
-15.9%
$92.0M$77.4M

Cash decreased 15.9% — monitor burn rate and upcoming capital needs.

LANGUAGE CHANGES
NEW — 2026-03-02
PRIOR — 2025-03-27
ADDED
As of February 25, 2026 , the registrant had 53,867,115 shares of common stock ($0.0001 par value) outstanding.
Overview We are a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology.
Through this approach, we have built a wholly-owned pipeline of oral small molecule product candidates focused on targets that have previously been considered difficult-to-drug.
Our FGFR3 Programs oral dabogratinib (formerly TYRA-300) for Urothelial Cancers and Skeletal Dysplasia Alterations in the protein receptor FGFR3 are a validated driver in multiple indications with large market opportunities: urothelial cancers and skeletal dysplasia conditions.
Our lead program, oral dabogratinib, was designed to be more selective for FGFR3 over FGFR1, FGFR2, and FGFR4 to minimize off-target side effects, providing potential clinical advantages over less selective first-generation compounds and potentially addressing key unmet needs across both urothelial cancers and skeletal dysplasia conditions.
To date, oral dabogratinib has been administered to over 100 participants across multiple clinical studies.
We demonstrated initial clinical proof-of-concept results with oral dabogratinib in the SURF301 study, a Phase 1 proof-of-concept study in metastatic urothelial carcinoma (mUC).
Oral dabogratinib demonstrated encouraging anti-tumor activity and was generally well-tolerated, with infrequent FGFR2- and FGFR1-associated toxicities.
Response, safety, pharmacokinetics (PK) / pharmacodynamics (PD) and circulating tumor DNA (ctDNA) data from this study were leveraged to select doses that have the potential to achieve our target product profile for efficacy and safety in our Phase 2 trials and beyond.
We are currently advancing oral dabogratinib in three Phase 2 trials for three outsized market indications: SURF303, evaluating the treatment of low-grade upper tract urothelial carcinoma (LG-UTUC); SURF302, evaluating the treatment of intermediate risk non-muscle invasive bladder cancer (IR NMIBC); and BEACH301, evaluating the treatment of achondroplasia (ACH) in children.
REMOVED
As of March 25, 2025 , the registrant had 53,089,957 shares of common stock ($0.0001 par value) outstanding.
Overview We are a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, with an initial focus on Fibroblast Growth Factor Receptor (FGFR) biology.
We have initially leveraged our SN P approach to develop TYRA-300, TYRA-200 and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first generation pan-FGFR inhibitors.
Our FGFR3 Programs TYRA-300 for Bladder Cancer and Skeletal Conditions Mutations in the protein receptor FGFR3 are a key driver in two indications with large market opportunities: bladder cancer and skeletal conditions.
Our lead program, TYRA-300, was designed to be more selective for FGFR3 over FGFR1, FGFR2, and FGFR4 to minimize off-target side effects, providing potential clinical advantages over less selective first-generation compounds and potentially addressing key unmet needs across both bladder cancer and skeletal conditions.
TYRA-300 is to be evaluated in three Phase 2 studies: SURF301, for the treatment of metastatic urothelial carcinoma (mUC); SURF302, for the treatment of non-muscle invasive bladder cancer (NMIBC); and BEACH301, for the treatment of pediatric achondroplasia (ACH).
SURF301 for mUC: This ongoing study is an international, multi-center, open label Phase 1/2 clinical trial that was designed to determine the optimal and maximum tolerated doses (MTD), and the recommended Phase 2 dose (RP2D) of TYRA-300, as well as to evaluate the preliminary antitumor activity of TYRA-300.
In late October 2024, we reported interim data that in patients with FGFR3+ mUC who received doses 90 mg once daily (QD), 6 out of 11 (54.5%) patients achieved a confirmed partial response (PR).
Preliminary data, as of the August 15, 2024 data cutoff, suggested TYRA-300 was generally well-tolerated, with infrequent FGFR2- and FGFR1-associated toxicities.
SURF302 for NMIBC: This study is an open-label Phase 2 clinical trial evaluating the efficacy and safety of TYRA-300 at lower doses (50 and 60mg QD) in participants with FGFR3-altered low-grade, intermediate risk (IR) NMIBC.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →